3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
CNS
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Genitourinary
1
Breast
1
Conditions
Multiple Myeloma
930
Lymphoma
113
Neoplasms, Plasma Cell
93
Recurrence
92
Lymphoma, Non-Hodgkin
68
Hematologic Neoplasms
62
Immunoglobulin Light-chain Amyloidosis
61
Neoplasms
54
Smoldering Multiple Myeloma
51
Leukemia, Myeloid, Acute
51
Leukemia
51
Myelodysplastic Syndromes
48
Leukemia, Lymphocytic, Chronic, B-Cell
46
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Hodgkin Disease
38
Leukemia, Plasma Cell
26
Myeloproliferative Disorders
24
Monoclonal Gammopathy of Undetermined Significance
23
Lymphoma, Large B-Cell, Diffuse
23
Lymphoma, Mantle-Cell
22
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
22
Breast Neoplasms
22
Amyloidosis
22
Primary Myelofibrosis
21
Lymphoma, Follicular
21
Waldenstrom Macroglobulinemia
20
Ovarian Neoplasms
18
Lymphoma, B-Cell, Marginal Zone
17
Lymphoma, B-Cell
17
Colorectal Neoplasms
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fasting
×
Plasma cell
×
1 year
×
Clear all
NCT05565638
2025-09-25
PROFAST
Dana-Farber Cancer Institute
Phase NA
Completed
23 enrolled